Geode Capital Management LLC Raises Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Geode Capital Management LLC boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 656,130 shares of the company’s stock after buying an additional 28,076 shares during the period. Geode Capital Management LLC owned 2.11% of Medpace worth $218,031,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. R Squared Ltd purchased a new stake in shares of Medpace during the 4th quarter worth $30,000. SBI Securities Co. Ltd. bought a new position in Medpace in the fourth quarter worth about $31,000. Jones Financial Companies Lllp lifted its position in shares of Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after buying an additional 110 shares during the last quarter. Lindbrook Capital LLC boosted its holdings in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after buying an additional 29 shares in the last quarter. Finally, Assetmark Inc. grew its position in shares of Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company’s stock worth $57,000 after buying an additional 29 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Medpace stock opened at $287.11 on Friday. Medpace Holdings, Inc. has a fifty-two week low of $282.42 and a fifty-two week high of $459.77. The company has a market cap of $8.75 billion, a PE ratio of 22.73, a PEG ratio of 3.81 and a beta of 1.45. The business’s 50-day simple moving average is $331.56 and its two-hundred day simple moving average is $337.49.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Leerink Partnrs raised shares of Medpace to a “hold” rating in a research report on Monday, March 24th. Robert W. Baird increased their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Finally, Leerink Partners started coverage on Medpace in a research note on Monday, March 24th. They set a “market perform” rating and a $330.00 target price on the stock. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Medpace presently has a consensus rating of “Hold” and a consensus price target of $376.30.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.